W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Although it’s now considered a “fad diet" on many popular health websites, it’s a mind-boggling reality to reflect on how ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

A new report warns Mississippi could see the steepest drop off in health insurance coverage if Congress doesn’t vote to extend temporary health coverage subsidies at the end of next year.

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

A new phase 3 clinical trial found that Eli Lilly's weight loss drug Zepbound resulted in significantly greater weight loss than Wegovy. Over a 72-week period, patients taking Zepbound lost an average ...

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

If you’ve thought about losing weight lately, you’re not alone. And you’re far from the first guy to look up the best weight ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...